Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Gains from Investment Securities (2016 - 2023)

VYNE Therapeutics' Gains from Investment Securities history spans 7 years, with the latest figure at $65000.0 for Q4 2023.

  • For Q4 2023, Gains from Investment Securities changed N/A year-over-year to $65000.0; the TTM value through Sep 2024 reached $65000.0, down 56.38%, while the annual FY2023 figure was $214000.0, N/A changed from the prior year.
  • Gains from Investment Securities reached $65000.0 in Q4 2023 per VYNE's latest filing, down from $149000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $4.2 million in Q3 2019 to a low of -$1.4 million in Q3 2021.
  • Average Gains from Investment Securities over 4 years is $430830.3, with a median of $98481.5 recorded in 2019.
  • The largest YoY upside for Gains from Investment Securities was 2257.53% in 2021 against a maximum downside of 264.12% in 2021.
  • A 4-year view of Gains from Investment Securities shows it stood at -$92000.0 in 2019, then increased by 20.65% to -$73000.0 in 2020, then skyrocketed by 2257.53% to $1.6 million in 2021, then crashed by 95.87% to $65000.0 in 2023.
  • Per Business Quant, the three most recent readings for VYNE's Gains from Investment Securities are $65000.0 (Q4 2023), $149000.0 (Q1 2023), and $1.6 million (Q4 2021).